All Updates

All Updates

icon
Filter
M&A
Iktos acquires Synsight for undisclosed sum to enhance AI-driven drug discovery
AI Drug Discovery
Jul 8, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
Funding
Partnerships
MyFloraDNA launches crowdfunding campaign to address peanut allergies using CRISPR technology
Crop Biotech
Jul 19, 2024
Partnerships
Ecobloom Technologies partners with Harvest Today to enhance global farming practices
Smart Farming
Jul 19, 2024
Funding
Hyzon Motors announces registered direct offering to raise USD 4.5 million
Truck Industry Tech
Jul 19, 2024
AI Drug Discovery

AI Drug Discovery

Jul 8, 2024

Iktos acquires Synsight for undisclosed sum to enhance AI-driven drug discovery

M&A

  • Iktos has acquired AI and high-content cell imaging-based drug developer Synsight for an undisclosed amount.

  • Post-acquisition, Iktos plans to leverage Synsight's MT Bench technology, integrating it with Iktos Robotics, the AI-driven robotic synthesis platform developed by Iktos. This integration is expected to speed up and automate the testing of synthesized compounds, a process currently outsourced by Iktos.

  • T he merger will also help launch Iktos’ drug discovery programs targeting protein-protein and RNA-protein interactions, critical in diseases like cancer and neurodegenerative illnesses.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.